United States pharmaceutical maker, Pfizer, and biopharmaceutical company, Global Blood Therapeutics (GBT), on Monday, agreed that Pfizer would acquire GBT in an all-cash deal valued at 5.4 billion U.S. dollars.
Pfizer said the acquisition would drive growth by enhancing its work in rare hematology while reinforcing the company’s commitment to sickle cell disease research and treatment.
According to dpa, under the terms of the transaction, Pfizer will acquire all the outstanding shares of California-based GBT for 68.50 dollars per share in cash, for a total enterprise value of approximately 5.4 billion dollars, including debt and net of cash acquired.
READ ALSO: BioNTech, Pfizer to develop vaccine against shingles
The pharmaceutical company expects to finance the transaction with existing cash on hand.
The proposed transaction, unanimously approved by the Boards of Directors of both companies, is subject to customary closing conditions, including receipt of regulatory approvals and approval by GBT’s stockholders.
Jigawa State Governor Umar Namadi has lost his 24-year-old son, Abdulwahab. Abdulwahab’s demise was announced…
...Flags off construction of Itawure - Okemesi road Ekiti State Governor, Mr Biodun Oyebanji, on…
Premier League title contenders Chelsea suffered a first home defeat against Fulham since 1979 on…
One of Nigeria's leading platforms for accessing information on scholarships, grants, and educational opportunities, Check…
The Federal Government has condemned the allegations made in a viral video by the military…
Super Eagles striker, Victor Osimhen, has distributed 2,000 tricycles, bags of rice, cartons of noodles…
This website uses cookies.